Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study.
Carcinoma
Chemotherapy
Non-small-cell lung
Paclitaxel
Poor performance status
Quality of life
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
01
11
2022
accepted:
27
01
2023
medline:
24
7
2023
pubmed:
10
2
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
This phase II trial is designed to test whether the performance status (PS) of metastatic non-small cell lung cancer (mNSCLC) patients (pts) can improve with chemotherapy if their poor PS (Eastern Cooperative Oncology Group (ECOG) PS of ≥ 2) is due to disease burden rather than comorbidities. Age18-65 years, Charlson's comorbidity index < 9, serum albumin ≥ 3.5 g/dl, adequate bone marrow and organ function, & ECOG PS ≥ 2 as judged by the worst score of three independent physicians were administered 3 doses of weekly paclitaxel at 60 mg/m Forty-six patients were included with a median age of 56 years (interquartile range, IQR 54-59), 12 (26%) had comorbid conditions, and 87% with ECOG PS 3/4. PS improved in 11 pts at 4 weeks and in 7 beyond this time point. Grade 3/4 toxicities are seen in 20% (most common: anemia and diarrhea). At a median follow-up of 4.8 m (95% CI 3.27-14.9), the median progression-free survival and overall survival were 3.3 months (95% CI 2.36-5.6) and 6.8 months (95% CI 2.47-8.8), respectively. QoL improved for global QoL, role functioning, pain, dyspnea, insomnia, pain in the chest, pain in other parts, and worsened for alopecia and sore mouth. Abbreviated chemotherapy is a useful, well-tolerated strategy in carefully selected poor PS mNSCLC patients that can improve PS and QoL. Clinical trial information: CTRI/2020/01/022617.
Identifiants
pubmed: 36759393
doi: 10.1007/s00432-023-04617-1
pii: 10.1007/s00432-023-04617-1
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6399-6409Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ando M, Ando Y, Hasegawa Y et al (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85:1634–1639. https://doi.org/10.1054/bjoc.2001.2162
doi: 10.1054/bjoc.2001.2162
pubmed: 11742480
pmcid: 2363970
Belani CP, Ramalingam S, Perry MC et al (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non–small-cell lung cancer. JCO 26:468–473. https://doi.org/10.1200/JCO.2007.13.1912
doi: 10.1200/JCO.2007.13.1912
Blagden SP, Charman SC, Sharples LD et al (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89:1022–1027. https://doi.org/10.1038/sj.bjc.6601231
doi: 10.1038/sj.bjc.6601231
pubmed: 12966419
pmcid: 2376959
Bonomi P, Blumenthal G, Ferris AS et al (2018) Making lung cancer clinical trials more inclusive: recommendations for expanding eligibility criteria. J Thorac Oncol 13:748–751. https://doi.org/10.1016/j.jtho.2018.02.013
doi: 10.1016/j.jtho.2018.02.013
pubmed: 29793646
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
CTCAE (2017) Common Terminology Criteria for Adverse Events (CTCAE). 155
Facchinetti F, Mazzaschi G, Barbieri F et al (2020) First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer 130:155–167. https://doi.org/10.1016/j.ejca.2020.02.023
doi: 10.1016/j.ejca.2020.02.023
pubmed: 32220780
Felip E, Ardizzoni A, Ciuleanu T et al (2020) CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer 127:160–172. https://doi.org/10.1016/j.ejca.2019.11.019
doi: 10.1016/j.ejca.2019.11.019
pubmed: 32028209
Fg D, Maggio I, Massucci M et al (2020) ECOG performance status ≥ 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—a systematic review and meta-analysis of real world data. Lung Cancer. https://doi.org/10.1016/j.lungcan.2020.04.027
doi: 10.1016/j.lungcan.2020.04.027
Gridelli C, Peters S, Mok T et al (2022) First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. ESMO Open. https://doi.org/10.1016/j.esmoop.2021.100355
doi: 10.1016/j.esmoop.2021.100355
pubmed: 34922299
Helbekkmo N, Sundstrøm SH, Aasebø U et al (2007) Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97:283–289. https://doi.org/10.1038/sj.bjc.6603869
doi: 10.1038/sj.bjc.6603869
pubmed: 17595658
pmcid: 2360329
Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400. https://doi.org/10.1200/JCO.2008.18.7658
doi: 10.1200/JCO.2008.18.7658
pubmed: 19224850
Kancharla H, Gundu N, Pathak N et al (2020) Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: a retrospective analysis from routine clinical practice. Curr Probl Cancer 44:100550. https://doi.org/10.1016/j.currproblcancer.2020.100550
doi: 10.1016/j.currproblcancer.2020.100550
pubmed: 31987521
Kosmidis PA, Dimopoulos M-A, Syrigos K et al (2007) Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2:135–140
doi: 10.1016/S1556-0864(15)30041-1
pubmed: 17410029
Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006. https://doi.org/10.1001/jama.2014.3741
doi: 10.1001/jama.2014.3741
pubmed: 24846037
pmcid: 4163053
Lakshmaiah KC, Asati V, Babu KG et al (2018) Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B cell lymphoma. Eur J Haematol 100:644–648. https://doi.org/10.1111/ejh.13068
doi: 10.1111/ejh.13068
pubmed: 29569279
LC-13 (2017) Questionnaires—EORTC—Quality of Life: EORTC—Quality of Life. https://qol.eortc.org/questionnaires/ , https://qol.eortc.org/questionnaires/ . Accessed 29 Jul 2022
Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367. https://doi.org/10.1200/JCO.1994.12.2.360
doi: 10.1200/JCO.1994.12.2.360
pubmed: 8113844
Lee SM, Schulz C, Prabhash K, Han B, Szczesna A, Cortinovis DL, Rittmeyer A, Vicente-Baz D, Califano R, Tuan Anh L, Liu G, Cappuzzo F, Reyes Contreras JG, Reck M, Hu Y, Morris S, Hoeglander EK, Connors M, Vollan HKM, Peters S (2022) IPSOS: results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Ann Oncol 33(suppl 7):S808–S869. https://doi.org/10.1016/annonc/annonc1089
doi: 10.1016/annonc/annonc1089
Leong SS, Toh CK, Lim WT et al (2007) A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2:230–236. https://doi.org/10.1097/JTO.0b013e318031d06f
doi: 10.1097/JTO.0b013e318031d06f
pubmed: 17410046
Lilenbaum RC, Cashy J, Hensing TA et al (2008) Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3:125–129. https://doi.org/10.1097/JTO.0b013e3181622c17
doi: 10.1097/JTO.0b013e3181622c17
pubmed: 18303431
Lobefaro R, Viscardi G et al (2021) Immunotherapy in advanced non-small cell lung cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2020.12.027
doi: 10.1016/j.lungcan.2020.12.027
pubmed: 33421923
Middleton G, Brock K, Savage J et al (2020) Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(20)30033-3
doi: 10.1016/S2213-2600(20)30033-3
pubmed: 32199466
Morabito A, Gebbia V, Di Maio M et al (2013) Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 81:77–83. https://doi.org/10.1016/j.lungcan.2013.04.008
doi: 10.1016/j.lungcan.2013.04.008
pubmed: 23643177
Myers J, Gardiner K, Harris K et al (2010) Evaluating correlation and interrater reliability for four performance scales in the palliative care setting. J Pain Symptom Manage 39:250–258. https://doi.org/10.1016/j.jpainsymman.2009.06.013
doi: 10.1016/j.jpainsymman.2009.06.013
pubmed: 20152588
Non-Small Cell Lung Cancer Collaborative Group (2010) Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007309.pub2
doi: 10.1002/14651858.CD007309.pub2
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
doi: 10.1097/00000421-198212000-00014
pubmed: 7165009
Patel A, Goldstein DA, Tannock IF (2022) Improving access to immunotherapy in low- and middle-income countries. Ann Oncol 33:360–361. https://doi.org/10.1016/j.annonc.2022.01.003
doi: 10.1016/j.annonc.2022.01.003
pubmed: 35033637
Radzikowska E, Głaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 13:1087–1093. https://doi.org/10.1093/annonc/mdf187
doi: 10.1093/annonc/mdf187
pubmed: 12176788
Rami-Porta R, Bolejack V, Giroux DJ et al (2014) The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 9:1618–1624. https://doi.org/10.1097/JTO.0000000000000334
doi: 10.1097/JTO.0000000000000334
pubmed: 25436796
Reck M, Rodríguez-Abreu D, Robinson AG et al (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 39:2339–2349. https://doi.org/10.1200/JCO.21.00174
doi: 10.1200/JCO.21.00174
pubmed: 33872070
pmcid: 8280089
Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808–5815. https://doi.org/10.1200/JCO.2009.21.9766
doi: 10.1200/JCO.2009.21.9766
pubmed: 19884554
pmcid: 2793001
Sculier JP, Lafitte JJ, Paesmans M et al (2007) Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30:1186–1192. https://doi.org/10.1183/09031936.00034507
doi: 10.1183/09031936.00034507
pubmed: 17690124
Sehgal K, Gill RR, Widick P et al (2021) Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open 4:e2037120. https://doi.org/10.1001/jamanetworkopen.2020.37120
doi: 10.1001/jamanetworkopen.2020.37120
pubmed: 33570575
pmcid: 7879233
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10. https://doi.org/10.1016/0197-2456(89)90015-9
doi: 10.1016/0197-2456(89)90015-9
pubmed: 2702835
Singh A, Kapoor A, Noronha V et al (2022) ALK-positive advanced non-small cell lung cancer patients with poor performance status: outcomes in a real-world scenario. Ecancermedicalscience 16:1407. https://doi.org/10.3332/ecancer.2022.1407
doi: 10.3332/ecancer.2022.1407
pubmed: 36072236
pmcid: 9377804
Sørensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67:773–775. https://doi.org/10.1038/bjc.1993.140
doi: 10.1038/bjc.1993.140
pubmed: 8471434
pmcid: 1968363
Suidan AM, Roisman L, Belilovski Rozenblum A, et al (2019) Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. JGO 1–8. https://doi.org/10.1200/JGO.18.00216
Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. JCO 40:611–625. https://doi.org/10.1200/JCO.21.01626
doi: 10.1200/JCO.21.01626
Tang M, Lee CK, Lewis CR et al (2022) Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. Lung Cancer 166:40–48. https://doi.org/10.1016/j.lungcan.2022.01.024
doi: 10.1016/j.lungcan.2022.01.024
pubmed: 35152172
Tryakin A, Fedyanin M, Bulanov A et al (2018) Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol 144:1817–1823. https://doi.org/10.1007/s00432-018-2695-4
doi: 10.1007/s00432-018-2695-4
pubmed: 29974210
Zhao L, Leung L-H, Wang J et al (2017) Association between Charlson comorbidity index score and outcome in patients with stage IIIB–IV non-small cell lung cancer. BMC Pulm Med 17:112. https://doi.org/10.1186/s12890-017-0452-0
doi: 10.1186/s12890-017-0452-0
pubmed: 28806935
pmcid: 5556668
Zukin M, Barrios CH, Pereira JR et al (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31:2849–2853. https://doi.org/10.1200/JCO.2012.48.1911
doi: 10.1200/JCO.2012.48.1911
pubmed: 23775961